Analyst Reco. Bolt Biotherapeutics, Inc.

Equities

BOLT

US0977022039

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 12/05/2026 am IST			5-day change	1st Jan Change
4.700 ^USD	+0.64%		-7.11%	-14.05%

13/03	Bolt Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12/03	Bolt Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI

Analyst Reco.

15/24/15	Leerink Partners Downgrades Bolt Biotherapeutics to Market Perform From Outperform, Adjusts PT to $1 From $3	MT
15/24/15	Guggenheim Downgrades Bolt Biotherapeutics to Neutral From Buy	MT
15/24/15	HC Wainwright Downgrades Bolt Biotherapeutics to Neutral From Buy	MT
15/24/15	Stifel Downgrades Bolt Biotherapeutics to Hold From Buy, Adjusts Price Target to $1.50 From $6	MT
12/23/12	SVB Securities Upgrades Bolt Biotherapeutics to Outperform From Market Perform, Price Target is $4	MT
24/23/24	Morgan Stanley Cuts Price Target on Bolt Biotherapeutics to $3 From $5, Maintains Equal-Weight Rating	MT
04/22/04	HC Wainwright Starts Bolt Biotherapeutics at Buy With $8 Price Target	MT
11/22/11	Stifel Nicolaus Lowers Price Target for Bolt Biotherapeutics to $7 From $13, Maintains Buy Rating	MT
11/22/11	SVB Securities Downgrades Bolt Biotherapeutics to Market Perform from Outperform, Adjusts Price Target to $4 from $8	MT
17/22/17	Morgan Stanley Adjusts Bolt Biotherapeutics' Price Target to $5 from $7, Keeps Equalweight Rating	MT
16/22/16	Stifel Adjusts Bolt Biotherapeutics' Price Target to $13 From $16, Reiterates Buy Rating	MT
01/22/01	Morgan Stanley Adjusts Bolt Biotherapeutics' Price Target to $7 from $11, Keeps Equalweight Rating	MT
06/22/06	Morgan Stanley Downgrades Bolt Biotherapeutics to Equalweight from Overweight, Adjusts Price Target to $11 from $45	MT
07/21/07	Stifel Adjusts Bolt Biotherapeutics' Price Target to $19 From $34, Reiterates Buy Rating	MT
10/21/10	SVB Leerink Adjusts Price Target on Bolt Biotherapeutics to $33 from $35, Keeps Outperform Rating	MT
17/21/17	BOLT BIOTHERAPEUTICS : SVB Leerink Raises Bolt Biotherapeutics' Price Target to $35 From $34, Maintains Outperform Rating	MT
06/21/06	BOLT BIOTHERAPEUTICS : SVB Leerink Adjusts Price Target on Bolt Biotherapeutics to $37 From $36, Maintains Outperform Rating	MT
02/21/02	BOLT BIOTHERAPEUTICS : Morgan Stanley Starts Bolt Biotherapeutics at Overweight With $45 Price Target	MT
02/21/02	BOLT BIOTHERAPEUTICS : SVB Leerink Starts Bolt Biotherapeutics at Outperform With $36 Price Target	MT
02/21/02	BOLT BIOTHERAPEUTICS : Stifel Starts Bolt Biotherapeutics at Buy With $40 Price Target	MT
02/21/02	BOLT BIOTHERAPEUTICS : Guggenheim Starts Bolt Biotherapeutics at Buy With $42 Price Target	MT